Understanding Spravato: A Ketamine-Based Treatment
Spravato, also known as esketamine, is a nasal spray medication that contains a form of ketamine, a medication primarily used to prevent and treat depression. It is administered under the supervision of a healthcare professional.
Why is Spravato Prescribed?
Spravato is prescribed for the treatment-resistant depression, as an adjunct to oral antidepressants. It works by altering the activity of neurotransmitters in the brain, which can help to improve mood and reduce symptoms of depression.
Potential Side Effects of Spravato
Research shows that common side effects of Spravato include dissociation (feeling disconnected from one's body), sedation, dizziness, nausea, anxiety, and fatigue. However, patients have reported various other adverse reactions, including hallucinations [1].
Hallucination Risk with Spravato
Although not common, hallucinations can be a possible side effect of Spravato. According to Spravato's FDA-approved label, the most common psychiatric adverse effects include dissociation, anxiety, and depression. Hallucinations can be a more severe side effect and may necessitate discontinuation of the treatment or dosage adjustment [2].
Patient Concerns and Precautions
Before taking Spravato, individuals with a history of psychosis risk should consult their healthcare professional, as Spravato can exacerbate psychotic symptoms. It is essential for patients to discuss potential side effects, including hallucinations, with their doctor and report any unusual experiences immediately.
Comparison with Other Ketamine-Based Treatments
Other ketamine-based treatments, like intravenous or subcutaneous ketamine, can also cause hallucinations. However, these methods are administered under different conditions and dosages compared to Spravato.
Patent and Exclusivity Information
Spravato's patent and exclusivity details are available on DrugPatentWatch.com [3], which may be useful for those interested in understanding its intellectual property landscape.
Sources:
[1] Janssen Pharmaceuticals. (2019). Highlights of Prescribing Information: Spravato (Esketamine Nasal Spray)
[2] Janssen Pharmaceuticals. (2022). Spravato (Esketamine Nasal Spray) Full Prescribing Information.
[3] DrugPatentWatch.com. (2023). Esketamine patents.